A Prospective Randomized Multicenter Controlled Trial on Salvianolate for Treatment of Unstable Angina Pectoris in A Chinese Elderly Population

Hua CUI; Xiao-ying LI; Xue-wen GAO; Xiang LU; Xiu-ping WU; Xiao-fei WANG; Xiang-qing ZHENG; Kui HUANG; Feng LIU; Zhi LUO; Hui-shu YUAN; Gang SUN; Jian KONG; Xiao-hong DU; Jin ZHENG; Hong-ying LIU; Wen-ju ZHANG

doi:10.1007/s11655-019-2710-x

Your Location：

Home >

Browse articles >

A Prospective Randomized Multicenter Controlled Trial on Salvianolate for Treatment of Unstable Angina Pectoris in A Chinese Elderly Population

Original Article | Updated：2021-08-27

- A Prospective Randomized Multicenter Controlled Trial on Salvianolate for Treatment of Unstable Angina Pectoris in A Chinese Elderly Population
- Chinese Journal of Integrative Medicine Vol. 25, Issue 10, Pages: 728-735(2019)
- Affiliations：
  
  1.Department of Geriatric Cardiology, the General Hospital of the People's Liberation Army, Beijing (100853), China
  2.Department of Geriatric Clinic, Inner Mongolia People's Hospital, Hohhot (010017), China
  3.Department of Cardiology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing (210011), China
  4.Second Department of Cadre's Ward, the First Affiliated Hospital of Harbin Medical University, Harbin (150001), China
  5.Department of Cadre Health Care, Tianjin First Central Hospital, Tianjin (300192), China
  6.Department of Cardiovascular Medicine, Chongqing General Hospital, Chongqing (400013), China
  7.Department of Geriatrics, Shenyang Red Cross Hospital, Shenyang (110063), China
  8.Department of Geriatric Cardiology, Guangzhou First People's Hospital, Guangzhou (510180), China
  9.Department of Cardiology, Beijing Geriatric Hospital, Beijing (100095), China
  10.the Second Department of Cardiology, the Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin (150009), China
  11.Department of Cardiology, Guizhou Province Hospital of Traditional Chinese Medicine, Guiyang (550001), China
  12.Department of Cadre's Ward, the First Bethune Hospital of Jilin University, Changchun (130021), China
  13.Department of Cadre Health Care, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province (325000), China
  14.Medical Department, Shanghai Green Valley Pharmaceutical Co., Ltd., Shanghai (201203), China
  15.China Health Promotion Foundation, Beijing (100161), China
- Author bio：
  
  Correspondence to: Dr. LI Xiao-ying, Tel: 86-10-66876271, E-mail: xyli301@163.com
- Funds：
- DOI：10.1007/s11655-019-2710-x
  CLC：
- Published：01 October 2019，
  
  Accepted：22 July 2019
Scan for full text
Hua CUI, Xiao-ying LI, Xue-wen GAO, et al. A Prospective Randomized Multicenter Controlled Trial on Salvianolate for Treatment of Unstable Angina Pectoris in A Chinese Elderly Population. [J]. Chinese Journal of Integrative Medicine 25(10):728-735(2019)
DOI：

Hua CUI, Xiao-ying LI, Xue-wen GAO, et al. A Prospective Randomized Multicenter Controlled Trial on Salvianolate for Treatment of Unstable Angina Pectoris in A Chinese Elderly Population. [J]. Chinese Journal of Integrative Medicine 25(10):728-735(2019) DOI： 10.1007/s11655-019-2710-x.

摘要

Abstract

Objective:

To evaluate the efficacy and safety of salvianolate in elderly patients with unstable angina pectoris (UAP).

Methods:

A prospective double-blind randomized placebo-controlled multicenter trial in elderly patients with UAP from 13 third-grade class-A hospitals in China was performed. A total of 318 patients were randomly allocated in a 1:1 ratio to an experimental group (160 patients) and a control group (158 patients). The experimental group was treated with salvianolate for 14 days on the basis of conventional medicine

and the control group was given a placebo for 14 days with the same criteria. Follow-up was lasted 28 days in both groups. The primary endpoint was biweekly frequency of angina pectoris attacks. The secondary endpoints included biweekly dosage of nitroglycerin

the Seattle Angina Questionnaire

angina pectoris severity and duration

myocardial injury markers

high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP)

as well as major adverse cardiovascular events (MACEs). Safety was assessed according to adverse events and serious adverse events.

Results:

Baseline characteristics were similar between treatment groups. Compared with those in the control group

the frequency of biweekly angina attacks (2.92 vs . 4.08

=0.025)

the biweekly dosage of nitroglycerin

as well as the severity and duration of angina attacks (

0.01) were reduced by salvianolate. The Seattle Angina Questionnaire score was also significantly improved in the experimental group than in the control group (

0.05). No significant differences were observed between the two groups with respect to the incidence of MACEs. Salvianolate was well tolerated.

Conclusions:

Salvianolate appear to have efficacy and well tolerated for elderly patients with UAP. [ClinicalTrials.gov identifier: NCT03037047]

关键词

Keywords

Salvianolateunstable angina pectoriselderlyefficacy

references

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia

Efficacy and Safety of Jianpi Jieyu Decoction for Patients with Mild-to-Moderate Depression of Xin (Heart)-Pi (Spleen) Deficiency Syndrome: A Multi-centre Randomized Controlled Study

Indian Traditional Treatments for Psoriasis: A Critical Appraisal of Available Evidence Supporting Efficacy

Efficacy and Safety of Mulberry Twig Alkaloids Tablet for Treatment of Type 2 Diabetes: A Randomized, Double-Blind,Placebo-Controlled Multicenter Clinical Study

Usage of Chinese Herbs in Cancer Patients in Southern China: A Survey

Related Author

No data

Related Institution

Graduate School, China Academy of Chinese Medical Sciences

Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences

Department of Encephalopathy, Xiyuan Hospital, China Academy of Chinese Medical Sciences

Xiyuan Clinical Medical College, Beijing University of Chinese Medicine

First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰